FDA OKs Canagliflozin to Curtail Diabetic Kidney Disease

Share this post

Results of CREDENCE lead to FDA approval for canagliflozin to slow kidney disease progression and reduce the risk of heart failure hospitalization in adults with type 2 diabetes.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply